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Abstract 
Objective: Risperidone has been found efficacious for decreasing severe tantrums, aggression, and 
self-injurious behavior in children and adolescents with autistic disorder (autism). The authors report on 
whether risperidone improves the core symptoms of autism, social and communication impairment and 
repetitive and stereotyped behavior. 
Method: The database from an 8-week double-blind, placebo-controlled trial (N= 101) and 
16-week open-label continuation study (N=63) of risperidone for children and adolescents with autism was 
used to test for drug effects on secondary outcome measures: scores on the Ritvo-Freeman Real Life Rating 
Scale, the Children’s Yale-Brown Obsessive Compulsive Scale, and the maladaptive behavior domain of 
the Vineland Adaptive Behavior Scales. 
Results: Compared to placebo, risperidone led to a significantly greater reduction in the overall 
score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor 
behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV). No 
statistically significant difference was observed, however, on the subscale for social relatedness (subscale 
II) or language (subscale V). Risperidone also resulted in significantly greater reductions in scores on the 
Children’s Yale-Brown Obsessive Compulsive Scale and Vineland maladaptive behavior domain. This 
pattern of treatment response was maintained for 6 months. 
Conclusions: Risperidone led to significant improvements in the restricted, repetitive, and 
stereotyped patterns of behavior, interests, and activities of autistic children but did not significantly change 
their deficit in social interaction and communication. Further research is necessary to develop effective 
treatments for the core social and communicative impairments of autism. 
Autistic disorder (autism) is a pervasive developmental disorder whose core symptoms 
are a qualitative impairment in social interaction and communication and restricted repetitive and 
stereotyped patterns of behavior, interests, and activities. Children with autism frequently have 
associated behavioral disturbances, such as severe tantrums, aggression, and self-injury, which 
can profoundly impair their functioning. In the initial study by the Autism Network of the 
Research Units on Pediatric Psychopharmacology, treatment with the atypical antipsychotic 
risperidone resulted in a significant improvement of these associated maladaptive behaviors (1). 
Less clear, however, is whether risperidone can also improve the core symptoms of autism. This 
article describes an attempt to address this clinically important issue. The rationale for choosing 
risperidone as the initial drug of investigation (2), the development of the assessment strategy 
(3), and the design and other methodological challenges of the study (4) are described elsewhere. 
In the initial 8-week multisite randomized, double-blind, placebo-controlled trial, the 
primary outcome measures were the irritability subscale of the Aberrant Behavior Checklist (5) 
and the Clinical Global Impression (CGI) improvement scale (6). A positive responder was 
defined as any child who showed a 25% reduction on the irritability subscale and who was rated 
as much improved or very much improved (i.e., 2 or 1, respectively) on the CGI improvement 
scale. According to these treatment response criteria, 34 (69%) of the 49 children randomly 
assigned to risperidone were categorized as responders versus six (12%) of the 52 children given 
placebo. 
At the end of the 8-week controlled trial, subjects who were initially assigned to placebo 
who did not respond were eligible to receive an 8-week trial of open-label risperidone. Subjects 
who showed a positive response to risperidone in either the 8-week controlled study or the 
8-week open-label trial were offered enrollment in a 16-week open-label continuation phase (7). 
This phase of the study allowed for a determination of the maintenance of improvement in the 
symptoms of tantrums, aggression, and self-injury over an extended period of time. 
In addition to the primary outcome variables, the study incorporated a number of 
secondary outcome measures, including the Ritvo-Freeman Real Life Rating Scale (8), the 
Children’s Yale-Brown Obsessive Compulsive Scale (9), and the maladaptive behavior domain 
of the Vineland Adaptive Behavior Scales (10). These scales were included in order to determine 
the effects of risperidone on target symptom domains beyond those of tantrums, aggression, and 
self-injury. 
The Ritvo-Freeman Real Life Rating Scale includes subscales that measure “social 
relationship to people” and “language.” The items in these subscales cover the first two DSM-IV 
diagnostic domains for autism: qualitative impairment in social interaction and communication, 
respectively. The compulsion scale of the Children’s Yale-Brown Obsessive Compulsive Scale is 
designed to measure repetitive behavior. This scale captures symptoms similar to those defined 
by the third DSM-IV diagnostic criterion for autism, restricted repetitive and stereotyped patterns 
of behavior, interests, and activities. Thus, these secondary measures allowed for an exploratory 
analysis of the effects of risperidone on the core symptom domains of autism. 
The original report (1) summarized the results on the primary outcome instruments, and a 
secondary methodological report provided results on parent-chosen, clinician-rated target 
symptoms (11). In the current analysis, using the findings on all remaining outcome measures, 
we tested the hypothesis that risperidone is superior to placebo for reducing repetitive behavior 
and that it improves measures of social relatedness and impaired communication. We also 
evaluated whether any improvements in these domains were maintained over the 16-week 
open-label continuation treatment phase. 
Method 
Participants 
The study sites included Indiana University, the Kennedy Krieger Institute at Johns 
Hopkins University, Ohio State University, the University of California at Los Angeles, and 
Yale University. The protocol was approved by the institutional review board at each site, and 
written informed consent was obtained from a parent or legal guardian before enrollment. 
The details of the study participants are described elsewhere (1, 7). Briefly, they were 
101 children and adolescents between the ages of 5 and 17 years (mean age=8.8 years, SD=2.7); 
82% were male. They met the DSM-IV criteria for a diagnosis of autistic disorder, which was 
corroborated by the Autism Diagnostic Interview—Revised (12), and they had impairing 
behavioral symptoms, such as severe tantrums, aggression, or self-injurious behavior. 
These subjects were randomly assigned to 8 weeks of risperidone (dose range=0.5-3.5 
mg/day, mean=1.8 mg/day, SD=0.7) or placebo in a double-blind trial. On the primary outcome 
measures, the Aberrant Behavior Checklist irritability subscale and the CGI improvement scale, 
risperidone was superior to placebo (p<0.001) (1). Thirty-four (69%) of 49 subjects showed a 
positive response to risperidone during the 8-week double-blind study, and 29 (63%) of 46 
subjects responded to risperidone in the 8-week open-label trial for the nonresponders in the 
placebo group. Thus, a total of 63 subjects entered the 16-week continuation phase. At the 
beginning of the extension phase, there were no differences between these two groups in the scores 
on the irritability subscale of the Aberrant Behavior Checklist or in the distribution of CGI severity 
scores. Therefore, the two groups were combined in the efficacy analysis. A detailed description 
of the baseline characteristics of this group are described elsewhere (7). Following the 16-week 
open-label continuation phase, 83% of the subjects continued to be rated as much improved or 
very much improved (2 or 1 on the CGI improvement scale). The mean daily dose of risperidone 
for the subjects beginning the 16-week continuation phase was 2.0 mg (SD=1.2). Over the course 
of the 16-week open-label treatment, there was a modest increase (6%) to a final mean daily dose 
of risperidone of 2.1 mg (SD=0.8). 
Ritvo-Freeman Real Life Rating Scale 
This scale was developed to evaluate the effects of treatments on symptomatic behaviors 
in patients with the syndrome of autism (8). It was designed as a direct observation measure that 
could be applicable to patients in their natural settings. Direct observation is one way of 
compensating for a patient’s limited ability to communicate (3). The Ritvo-Freeman Real Life 
Rating Scale has been used to measure change in behavioral symptoms in controlled drug 
treatment studies involving children (13), as well as adults (14, 15), with autism. The studies with 
adults, however, involved only one investigative site and a single rater. For the current study, even 
with extensive and repeated training and standardization of procedures for the 30-minute 
observation period, we were unable to attain acceptable reliability across the five study sites for 
direct observation. We next considered videotaping the 30-minute observation protocol for later 
coding/rating by reliable raters. However, the validity of videotaping live examinations as a way 
of recording a representative sample of the subject’s behavior seemed questionable (16). 
Therefore, we modified the Ritvo-Freeman Real Life Rating Scale to convert it from an 
observational measure to a parent rating scale. In the adapted version, the original scales were 
retained and the items were rephrased to allow parents to rate each of the 47 items from 0 to 3 as 
described in the following. 
Like the original instrument, our modified Ritvo-Freeman Real Life Rating Scale included 
subscales for assessing sensory motor behaviors (e.g., hand flapping, rocking, pacing) (subscale 
I), social relatedness (e.g., appropriate responses to interaction attempts, initiation of appropriate 
physical interactions) (subscale II), affectual reactions (e.g., abrupt changes in affect, crying, 
temper outbursts) (subscale III), sensory responses (e.g., being agitated by noises, rubbing 
surfaces, sniffing self or objects) (subscale IV), and language (e.g., communicative use of 
language, initiation of appropriate verbal communication) (subscale V). Each of the five 
subscales contained a number of individual items that were scored on a 4-point scale: 0 indicated 
“never,” 1 signified “infrequently (occasionally),” 2 indicated “frequently (daily),” and 3 
represented “almost always.” The average of the mean values for each of the five subscale scores 
was determined to yield an overall score. The score on the Ritvo-Freeman Real Life Rating Scale 
increases as the number and frequency of symptoms of autism increase. A mathematical sign 
correction to subtract normal behavior is necessary on subscales II, IV, and V; this could result in 
negative values on some subscales.
       Results of Placebo-Controlled 




Interaction of  
Treatment With 
TImeMeasure From Ritvo-Freeman 
Real Life Rating Scale 
Baseline Week 4 Week 8 
Mean SD Mean SD Mean SD F (df=1, 87) p 
Subscale I: sensory motor behaviors       0.45 10.8 0.002 
 Risperidone 1.00 0.52 0.65 0.43 0.59 0.42    
 Placebo 0.93 0.58 0.83 0.47 0.91 0.60    
Subscale II: social relationship to people       0.68 — n.s. 
 Risperidone 0.60 0.43 0.20 0.43 0.15 0.42    
 Placebo 0.72 0.43 0.47 0.51 0.46 0.52    
Subscale III: affectual reactions       1.10 15.4 <0.001 
 Risperidone 1.68 0.64 1.00 0.67 0.88 0.56    
 Placebo 1.84 0.64 1.64 0.64 1.60 0.71    
Subscale IV: sensory responses       0.77 8.5 0.004 
 Risperidone 1.13 0.53 0.70 0.44 0.60 0.38    
 Placebo 1.21 0.53 0.98 0.54 1.07 0.54    
Subscale V: language       0.81 — n.s. 
 Risperidone 0.28 0.38 0.15 0.31 0.03 0.29    
 Placebo 0.46 0.42 0.30 0.39 0.34 0.41    
Overall       1.08 15.3 <0.001 
 Risperidone 0.94 0.36 0.54 0.36 0.45 0.31    
 Placebo 1.03 0.37 0.84 0.39 0.88 0.40    
TABLE 1. Scores on the Ritvo-Freeman Real Life Rating Scale of Children and Adolescents With Autism in a Placebo-Controlled Risperidone Trial 
and Open-Label Continuation Study 
The scale was administered at baseline and at the end of weeks 4 and 8 during the controlled trial and 
monthly thereafter for subjects who entered the 16-week open-label continuation phase of the study (i.e., 12, 16, 20, 
and 24 weeks after baseline). The parent or primary caregiver was asked to consider the child’s behavior over the past 
month. 
Children’s Yale-Brown Obsessive Compulsive Scale 
This scale is a reliable and valid semistructured clinician-rated measure of 
obsessive-compulsive symptom severity in children and adolescents with obsessive-compulsive 
disorder (OCD) (9). The Children’s Yale-Brown Obsessive Compulsive Scale is a modified version 
of the Yale-Brown Obsessive Compulsive Scale, which was developed for adults with OCD (17, 
18). Like the adult version, the scale for children is a 10-item clinician-rated, semi-structured 
instrument designed to assess the severity of OCD symptoms over the previous week. The 
overall structure, anchor points, and scoring of the original instrument were retained in the 
children’s version, but the wording of the probe questions was modified to make them more 
developmentally appropriate for children and adolescents. 
The severity of the endorsed obsessions is rated on five items: time spent, interference, 
associated distress, degree of resistance against the thoughts, and degree of control over 
obsessive thoughts. Each of these five items is rated on a 5-point ordinal scale: 0 indicates 
“none”; 1, “mild”; 2, “moderate”; 3, “severe”; and 4, “extreme.” The obsessions severity score is 
obtained by adding the scores for items 1 through 5 (range=0 to 20). There are five comparable 
severity items for compulsions (items 6 through 10), which are also scored from 0 to 4. The 
compulsion severity score is obtained by adding the scores on items 6 through 10 (range=0 to 
20). Summing the scores for all 10 items yields the total score on the Children’s Yale-Brown 
Obsessive Compulsive Scale (range=0 to 40). Because many children with autism have limited 
cognitive and verbal communication abilities, we used only the compulsion subscale of the 
Children’s Yale-Brown Obsessive Compulsive Scale (range=0-20). These cognitive and 
communication impairments may also limit the subject’s ability to describe his or her subjective 
experience concerning resistance and degree of control over repetitive behavior. For these items, 
we relied on the parent as the primary informant. Children with OCD typically describe distress 
associated with the performance of their unwanted rituals (19). By contrast, children and adults 
with autism often engage in self-stimulating or self-soothing stereotypic behaviors and do not 
appear distressed during the performance of repetitive behavior (20, 21). Because of these 
observations, the modified Children’s Yale-Brown Obsessive Compulsive Scale did not require 
the subject’s recognition that the behavior is excessive. To capture stereotypic behaviors, the 
scale’s symptom checklist was expanded to include repetitive behaviors associated with autism, 
such as spinning objects, staring, twirling, and repeating words and phrases. 
Reliability was established through multiple training sessions and co-rating of videotaped 
interviews. Each clinical rater had to achieve a criterion of ± 15% of the gold standard established 
by an experienced rater (L.S.). For example, if the gold standard rating total for a videotaped 
interview was 14, the other raters had to rate the same tape between 12 and 16 to qualify as a 
rater; if the gold standard was 10, they had to rate the tape between 9 and 11. Anyone who did not 
meet this criterion on four tapes underwent further training and rated additional tapes until 
qualified. The Children’s Yale-Brown Obsessive Compulsive Scale was administered by a blinded 
clinician at baseline and at the end of 2, 4, 6, and 8 weeks of the controlled drug study. This 
measure was also administered on a monthly basis during the 16-week open-label continuation 
phase (i.e., 12, 16, 20, and 24 weeks after baseline). The scores determined by the clinical rater 
were based on the information provided by the subject’s parent or primary caregiver during the 
interview regarding his or her child’s repetitive behavior over the interval since the last 
assessment. 
Maladaptive Behavior Domain of Vineland Adaptive Behavior Scales 
The maladaptive behavior domain of the Vineland Adaptive Behavior Scales (10) was 
completed by trained clinicians by means of a parent interview. The maladaptive behavior domain 
is divided into two subscales: part 1 consists of 27 items, and part 2 consists of nine items. Each 
item is scored on a 3-point scale where 0 indicates “no, never,” 1 indicates “sometimes or partially,” 
and 2 signifies “yes, usually.” Thus, the range of scores for part 1 was 0 to 54, the range for part 2 
was 0 to 18, and the range for the total score was 0 to 72. Part 1 includes mood- and 
anxiety-related along with hyperactivity, lying, cheating, bed-wetting, and others. Part 2 contains 
more severe symptoms, including psychosis, self-injury, and property destruction. These 
subscales have previously been shown to be sensitive to change with medication in 
pharmacological studies involving subjects with autism (14, 22). Ratings on this secondary 
outcome measure were obtained by interview at baseline, at week 8 of the placebo-controlled 
phase, and at the end of the 16-week open-label continuation phase of the study (i.e., 24 weeks 
after baseline). 
 Score in Open-Label Continuation Study 
(N=63)
 
Week 12 Week 16 Week 20 Week 24 
Mean SD Mean SD Mean SD Mean SD
0.59 0.43 0.54 0.42 0.54 0.49 0.60 0.49
0.06 0.42 0.04 0.45 0.02 0.46 0.00 0.42
0.89 0.62 0.81 0.44 0.87 0.60 0.78 0.58
0.55 0.40 0.48 0.39 0.50 0.42 0.45 0.37
0.07 0.34 0.05 0.38 0.06 0.39 0.10 0.36
0.43 0.34 0.38 0.31 0.40 0.39 0.39 0.35
Statistical Analysis 
The data were analyzed according to the intent-to-treat principle. The statistical tests 
were two-tailed, and p values of 0.05 or less were considered to indicate statistical significance. 
Bonferroni correction for multiple tests was not done because the different instruments measured 
different domains of functioning. For the 8-week controlled trial, the monthly and biweekly 
scores on the Ritvo-Freeman Real Life Rating Scale and the Children’s Yale-Brown Obsessive 
Compulsive Scale, respectively, were analyzed with the use of mixed-effects linear models in 
which the study group and site were the fixed effects and the outcome and time were the random 
effects (23). The mixed-effects approach makes full use of available data and allowed us to 
combine subject-specific scores on the Ritvo-Freeman Real Life Rating Scale and Children’s 
Yale-Brown Obsessive Compulsive Scale in order to estimate the slope of the regression line for 
each group over time. A strong downward trend in scores in the risperidone group, as compared 
with the placebo group, would indicate a statistically significant interaction between treatment 
and time. Site-by-treatment interactions that were not significant were removed from the final 
model. The parameters of the mixed-effects model were estimated with the use of SAS Proc 
Mixed software (24). Because the Vineland maladaptive behavior domain scales had insufficient 
data points for the mixed-effects model, analysis of covariance was used to compare groups 
during the placebo-controlled phase. 
For the 16-week open-label continuation phase, the monthly scores on the Ritvo-Freeman 
Real Life Rating Scale and the Children’s Yale-Brown Obsessive Compulsive Scale were 
analyzed with mixed-effects linear regression models in which time, site, and the site-by-time 
interaction were the fixed effects. The average slope of the regression line was calculated for 
each individual across time. Paired t tests of scores on the Vineland along with hyperactivity, 
lying, cheating, bed-wetting, and others. Part 2 maladaptive behavior domain scales were used to 
compare the values at the beginning of the 16-week open-label continuation phase with the 
scores at the end (week 24). 
 
FIGURE 1. Scores for Compulsions on the Children’s Yale-Brown Obsessive Compulsive Scale of 
Children and Adolescents in a Placebo-Controlled Risperidone Trial and Open-Label Continuation Study 
Results 
Ritvo-Freeman Real Life Rating Scale 
Risperidone significantly decreased the overall score on the Ritvo-Freeman scale and the 
scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale 
III), and sensory responses (subscale IV), but it had no statistically significant effect on the score 
on the subscale for social relatedness (subscale II) or language (subscale V). Table 1 shows the 
mean scores at baseline, the end of week 4, and the end of week 8, as well as the effect size, for 
each of the five subscales and the overall Ritvo-Freeman Real Life Rating Scale in each study 
group during the 8-week controlled phase of the study. The scores are also shown for the 
monthly measurements in the 16-week open-label continuation phase. There was no significant 
change in any of these measures over the course of the continuation phase. 
Children’s Yale-Brown Obsessive Compulsive Scale 
Figure 1 shows the mean scores at baseline and at the end of weeks 2, 4, 6, and 8 on the 
modified compulsion scale of the Children’s Yale-Brown Obsessive Compulsive Scale for each 
study group during the 8-week controlled phase of the study. The mean score went from 15.51 
(SD= 2.73) to 11.65 (SD=4.02) in the risperidone group compared to 15.18 (SD=3.88) to 14.21 
(SD=4.81) in the placebo group. There was a significant interaction between study group and 
time (F=8.21, df=1, 243, p=0.005); the effect size (Cohen’s d) was 0.55. The mean values are 
also shown for the 16-week open-label continuation phase. There was no significant change in 
this measure during the continuation.
 Measure From 
Maladaptive Behavior 
Domain of Vineland 
Adaptive Behavior Scales 
Score in Placebo-Controlled Trial Results of Placebo-Controlled Trial Score at Week 24: End of Open-
 (N= 101)  End-of-Study
Effect Size 
(Cohen’s d) 
Interaction of Treatment 
With Time 
 
Label Continuation Study 
Baseline Week 8 (N=63)  
Mean SD Mean SD F (df=1, 84) p Mean SD 
Part 1     1.17 34.2 <0.001   
Risperidone 24.89 6.91 14.89 5.93    16.55 6.87 
Placebo 25.22 5.72 22.97 5.99      
Part 2   0.49 6.7 0.02
Risperidone 8.37 2.59 5.45 3.25    5.04 3.20 
Placebo 8.29 3.66 7.30 3.45      
Total     1.03 26.6 <0.001   
Risperidone 33.26 8.38 20.34 7.93    21.60 9.50 
Placebo 33.51 8.29 30.27 8.87  
TABLE 2. Scores on the Maladaptive Behavior Domain of the Vineland Adaptive Behavior Scales of Children and Adolescents With Autism in a 
Placebo-Controlled Risperidone Trial and Open-Label Continuation Study 
Maladaptive Behavior Domain of Vineland Adaptive Behavior Scales 
Table 2 shows the mean scores at baseline and the end of week 8 for part 1, part 2, and 
the total maladaptive behavior domain for the risperidone and placebo groups. The mean values 
for these measures are also shown for the end of the 16-week open-label phase (week 24 of the 
study). There was a significant interaction between treatment and time for each of these scores 
during the 8-week controlled phase of the study. There was no significant change in these 
measures over the 16-week continuation phase. 
Discussion 
In this controlled study, risperidone was more efficacious than placebo for improving 
scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale 
III), and sensory responses (subscale IV) and the overall score on the Ritvo-Freeman Real Life 
Rating Scale. Risperidone was not significantly better than placebo for improving the first two 
core symptom domains of autism, impaired social relatedness and language usage, as measured 
with subscales II (social relationship to people) and V (language) of the Ritvo-Freeman scale. 
These findings are similar to those of a double-blind, placebo-controlled study of risperidone for 
adults with autism and pervasive developmental disorder not otherwise specified (15). It is 
interesting that in the present study there was a nearly significant difference between risperidone 
and placebo in the social domain, as measured on subscale II (social relationship to people) 
(p<0.07), as well as on the social withdrawal subscale of the Aberrant Behavior Checklist (1). 
These results can be explained by the fact that reducing interfering tantrums, aggression, and 
self-injury allows the individual to be more available for social interaction. Alternatively, it may 
be that the rating instruments used to measure change in the social domain in this study were not 
sensitive enough. This dilemma points to the need for reliable and valid rating scales that are also 
sensitive to change in measures of social relatedness for use in treatment studies involving 
subjects with autism. Scales like the Social Responsiveness Scale (25, 26) may prove more 
useful for this purpose in future studies. 
Restricted repetitive and stereotyped patterns of behavior, interests, and activities are the 
third core symptom domain of autism in DSM-IV. Although the types of repetitive phenomena 
demonstrated by persons with autism are different from those of individuals with OCD (21), the 
behaviors can cause significant impairment through time consumption and irritable reactions to 
interruptions (3, 27). In the current study, risperidone resulted in a significantly greater reduction 
of repetitive behavior than did placebo, as reflected in scores on the compulsion subscale of the 
modified Children’s Yale-Brown Obsessive Compulsive Scale. This result is also in agreement 
with that of the placebo-controlled study of risperidone for adults with autism, in which the drug 
led to a significant reduction in Yale-Brown Obsessive Compulsive Scale scores over 12 weeks 
(15). Moreover, this decrease in repetitive behavior parallels the reduction observed on the 
stereotypy subscale of the Aberrant Behavior Checklist described in our initial report (1) and on 
subscale IV (sensory responses) of the Ritvo-Freeman Real Life Rating Scale in the current 
study, affirming the positive effects of risperidone for this symptom domain. This finding is not 
surprising in light of previous studies of haloperidol for children with autism, in whom 
significant reductions of stereotypic behavior were observed (28). Commenting on antipsychotic 
drug research in patients with mental retardation, Aman (29) noted that various types of 
stereotypic behavior were often the most sensitive measures of treatment effect. Both haloperidol 
and risperidone are potent dopamine D2 receptor antagonists, which have previously been shown 
to reduce refractory symptoms of OCD in adults when combined with ongoing therapy with 
serotonin reuptake inhibitors (30, 31). 
Risperidone was also more efficacious than placebo for reducing scores on the total 
maladaptive behavior domain of the Vineland Adaptive Behavior Scales and on parts 1 and 2. 
Items in part 1 have been referred to as “minor maladaptive behaviors” and include symptoms 
found in attention deficit hyperactivity disorder, oppositional defiant disorder, and conduct 
disorder. A pilot placebo-controlled study of children and adolescents of normal intelligence with 
conduct disorder (32) and two large-scale double-blind, placebo-controlled studies of risperidone 
for children and adolescents with subaverage IQ and associated conduct problems (33, 34) 
previously showed the drug to be beneficial for these types of symptoms. Part 2 contains items 
considered “more serious maladaptive behaviors.” Among them, self-injurious behavior and 
property destruction have been shown to improve with risperidone, as measured by change in the 
score on the irritability subscale of the Aberrant Behavior Checklist, as described in the initial 
report from this study (1). 
As was observed with the primary outcome measures, the irritability subscale of the 
Aberrant Behavior Checklist and the CGI improvement scale (7), improvement in the secondary 
outcome measures described in this report was maintained during the 16-week continuation 
phase of the study. In addition, despite an additional 16 weeks of risperidone treatment, no 
statistically significant improvement was recorded in social relatedness or language usage, as 
measured by subscales II and V of the Ritvo-Freeman Real Life Rating Scale. 
A limitation of the current study was the use of two modified rating instruments, the 
modified Ritvo-Freeman Real Life Rating Scale and Children’s Yale-Brown Obsessive 
Compulsive Scale, for which reliability and validity have not yet been established. These 
modified instruments were used because there are no currently available instruments designed to 
measure change in these particular target symptom domains in this patient population. The 
psychometric properties of these modified instruments are currently being examined. 
In summary, the results of this analysis of secondary measures indicate that 8 weeks of 
treatment with risperidone is not significantly different from placebo for the qualitative 
impairment in social interaction and communication that characterize autism, but repetitive and 
stereotyped patterns of behavior, interests, and activities did improve. This pattern of response 
was maintained with 16 additional weeks of risperidone therapy. Further studies aimed at 
identifying effective treatments for the core social and communicative impairment of autism are 
warranted. 
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